(VIANEWS) – FNF Group of Fidelity National Financial (FNF), Inter Parfums (IPAR), Marriot Vacations Worldwide Corporation (VAC) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. FNF Group of Fidelity National Financial (FNF)
18.3% sales growth and 12.08% return on equity
Fidelity National Financial, Inc., together with its subsidiaries, provides various insurance products in the United States. The company operates through Title, F&G, and Corporate and Other segments. It offers title insurance, escrow, and other title related services, including trust activities, trustee sales guarantees, recordings and reconveyances, and home warranty insurance. The company also provides technology and transaction services to the real estate and mortgage industries; and mortgage transaction services, including title-related services and facilitation of production and management of mortgage loans. In addition, it offers annuity and life insurance products, such as deferred annuities that include fixed indexed, fixed rate, and immediate annuities, as well as indexed universal life insurance products. Further, the company engages in the real estate brokerage business. Fidelity National Financial, Inc. was founded in 1847 and is headquartered in Jacksonville, Florida.
Earnings Per Share
As for profitability, FNF Group of Fidelity National Financial has a trailing twelve months EPS of $3.04.
PE Ratio
FNF Group of Fidelity National Financial has a trailing twelve months price to earnings ratio of 16.23. Meaning, the purchaser of the share is investing $16.23 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.08%.
Volume
Today’s last reported volume for FNF Group of Fidelity National Financial is 779267 which is 28.93% below its average volume of 1096570.
Yearly Top and Bottom Value
FNF Group of Fidelity National Financial’s stock is valued at $49.35 at 11:22 EST, under its 52-week high of $53.96 and way above its 52-week low of $34.96.
2. Inter Parfums (IPAR)
12.5% sales growth and 19.36% return on equity
Inter Parfums, Inc., together with its subsidiaries, manufactures, markets, and distributes a range of fragrances and fragrance related products in the United States and internationally. It operates in two segments, European Based Operations and United States Based Operations. The company offers its fragrance and cosmetic products under the Boucheron, Coach, Jimmy Choo, Karl Lagerfeld, Kate Spade, Lanvin, Moncler, Montblanc, Rochas, S.T. Dupont, Van Cleef & Arpels, Abercrombie & Fitch, Anna Sui, Donna Karan, DKNY, Ferragamo, Graff, GUESS, Hollister, MCM, Oscar de la Renta, and Ungaro brands, as well as French Connection, Intimate, and Aziza names. It sells its products to department stores, specialty stores, duty free shops, beauty retailers, and domestic and international wholesalers, and distributors, as well as through e-commerce. The company was formerly known as Jean Philippe Fragrances, Inc. and changed its name to Inter Parfums, Inc. in July 1999. Inter Parfums, Inc. was founded in 1982 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Inter Parfums has a trailing twelve months EPS of $4.34.
PE Ratio
Inter Parfums has a trailing twelve months price to earnings ratio of 26.59. Meaning, the purchaser of the share is investing $26.59 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.36%.
3. Marriot Vacations Worldwide Corporation (VAC)
9.8% sales growth and 8.69% return on equity
Marriott Vacations Worldwide Corporation, a vacation company, develops, markets, sells, and manages vacation ownership and related products. It operates through two segments, Vacation Ownership and Exchange & Third-Party Management. The company manages vacation ownership and related products under the Marriott Vacation Club, Grand Residences by Marriott, Sheraton Vacation Club, Westin Vacation Club, Hyatt Residence Club, and Marriott Vacation Club Pulse brands. It also develops, markets, and sells vacation ownership and related products under The Ritz-Carlton Destination Club brand; and holds right to develop, market, and sell ownership residential products under The Ritz-Carlton Residences brand. In addition, the company offers exchange networks and membership programs, as well as provision of management services to other resorts and lodging properties through various brands, including Interval International, Trading Places International, Vacation Resorts International, and Aqua-Aston. The company sells its upscale tier vacation ownership products primarily through a network of resort-based sales centers and off-site sales locations. Marriott Vacations Worldwide Corporation was founded in 1984 and is headquartered in Orlando, Florida.
Earnings Per Share
As for profitability, Marriot Vacations Worldwide Corporation has a trailing twelve months EPS of $5.44.
PE Ratio
Marriot Vacations Worldwide Corporation has a trailing twelve months price to earnings ratio of 15.1. Meaning, the purchaser of the share is investing $15.1 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.69%.
4. Vertex Pharmaceuticals (VRTX)
8.2% sales growth and 24.38% return on equity
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Earnings Per Share
As for profitability, Vertex Pharmaceuticals has a trailing twelve months EPS of $13.89.
PE Ratio
Vertex Pharmaceuticals has a trailing twelve months price to earnings ratio of 28.55. Meaning, the purchaser of the share is investing $28.55 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.38%.
5. Gaming and Leisure Properties (GLPI)
6.3% sales growth and 17.32% return on equity
GLPI is engaged in the business of acquiring, financing, and owning real estate property to be leased to gaming operators in triple-net lease arrangements, pursuant to which the tenant is responsible for all facility maintenance, insurance required in connection with the leased properties and the business conducted on the leased properties, taxes levied on or with respect to the leased properties and all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties.
Earnings Per Share
As for profitability, Gaming and Leisure Properties has a trailing twelve months EPS of $2.71.
PE Ratio
Gaming and Leisure Properties has a trailing twelve months price to earnings ratio of 16.45. Meaning, the purchaser of the share is investing $16.45 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.32%.
Sales Growth
Gaming and Leisure Properties’s sales growth is 5.7% for the present quarter and 6.3% for the next.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jun 7, 2024, the estimated forward annual dividend rate is 3.04 and the estimated forward annual dividend yield is 6.75%.
Yearly Top and Bottom Value
Gaming and Leisure Properties’s stock is valued at $44.58 at 11:22 EST, way under its 52-week high of $50.06 and above its 52-week low of $41.80.
Revenue Growth
Year-on-year quarterly revenue growth grew by 5.8%, now sitting on 1.46B for the twelve trailing months.
